Amphetamin & MAOI

Critical Risk: Risk of hypertensive crisis

Critical RiskClass-based

Risk Assessment

Critical Risk

Amphetamine increases the release of catecholamines such as noradrenaline and dopamine, while MAO inhibitors block their breakdown. Combined, this can lead to a dangerous accumulation of catecholamines and the risk of a hypertensive crisis, with severely elevated blood pressure that can cause serious cardiovascular and neurological harm.

Pharmacological Mechanism

Efflux-basierter Monoaminüberschuss (Amphetamin) + Hemmung des Monoaminabbaus (MAO-Hemmer) = exponentiell erhöhte Serotoninbelastung und noradrenerge Krise

Mechanism data is language-neutral pharmacological notation.

Substance Profiles

Amphetamin

Stimulanzien

DAT-UmkehrtransportNET-UmkehrtransportTAAR1-Agonist

DATNETTAAR1

MAOI

Evidence Base

Curated Interaction DataAvailable

Data ProvenanceClass-based

Community Mentions0

Shared Receptors0

Safer Use Guidelines

Combining amphetamine with MAO inhibitors is documented as carrying a high risk of hypertensive crisis.
A severe headache, chest pain, visual disturbances or neurological symptoms after this combination require immediate emergency medical care.
MAO inhibitors can remain active for an extended period after the last dose, so the interaction risk persists even with a time gap.

This page is based on curated pharmacological data and/or community signals. It is intended for scientific education and harm reduction only. It does not replace professional medical advice. Not all interactions are covered — always consult a healthcare professional when in doubt. In emergencies, call your local emergency number.

Laden…

Risk Assessment

Critical Risk

Safer Use Guidelines

Combining amphetamine with MAO inhibitors is documented as carrying a high risk of hypertensive crisis.
A severe headache, chest pain, visual disturbances or neurological symptoms after this combination require immediate emergency medical care.
MAO inhibitors can remain active for an extended period after the last dose, so the interaction risk persists even with a time gap.